MTOR and non-small cell lung carcinoma: The enrichment results were focused on human disease-related pathways, including breast cancer, non-small cell lung cancer, pancreatic cancer, mammalian target of rapamycin (mTOR), vascular endothelial growth factor (VEGF), and forkhead box proteins of the class O subgroup (FoxO) signaling pathway (Figure 4D).